bg
dial

COMPETITION

SSP

(SHIONOGI Science Program)

We would like to invite innovative, cutting edge ideas from you.
We hope that together we can create superior pharmaceuticals for those who suffer from diseases all over the world, and fulfill their unmet medical needs.

Overview

Application details

Refer to the "SHIONOGI Science Program Application Guideline".

Eligible countries

Australia, Belgium, Denmark, France, Germany, Ireland, Italy, Luxembourg, New Zealand, the Netherlands, and the UK. Researchers must carry out their research in these countries.

Research budgets

Budgets will be a maximum of ¥15 million per year per project and will be finalized after selection.
Budgets are collaboration research budgets.

Application periods

9:00 am 16th January 2017 - 4:00 pm 24th February 2017
(The above dates and times are provided in JST; please check the corresponding dates and times for each country)

Application areas

  • ・ An innovative approach to target identification and/or technology platform in drug discovery for pain.
  • ・ An innovative approach to discovery of novel opioid analgesics without central side effects, such as psychological dependence, sedation and respiratory depression.
  • ・ A unique bioinformatics method to identify novel drug targets, biomarkers and pathogenesis of CNS disorders in emphasis on research to treat impairment of cognitive functions.
  • ・ An approach and/or technology to improve gastrointestinal mucosal permeability of beta-lactam antibiotics.
  • ・ A novel approach to cure (virus eradication) or to functional cure (permanent suppression of viral replication) of human immunodeficiency virus (HIV) infection.
  • ・ A novel approach to cure (virus eradication) or to functional cure (permanent suppression of viral replication) of hepatitis B virus (HBV) infection.
  • ・ A preclinical model of latent HIV infection.
  • ・ A preclinical model of latent HBV infection.
  • ・ A preclinical model of chronic human herpesvirus (HHV) infection.

Inquiries

Please make all inquiries via the "Inquiries Form".

Application guideline

Eligible countries

Australia, Belgium, Denmark, France, Germany, Ireland, Italy, Luxembourg, New Zealand, the Netherlands, and the UK.
Researchers must carry out their research in these countries.

Selection schedule and application countries

Primary selection

Application period

9:00 am 16th January 2017 - 4:00 pm 24th February 2017
(The above dates and times are provided in JST; please check the corresponding dates and times for each country)

Application method

Apply using the “Application Form”.
(Available language is English only.)
Shionogi will inform applicants of receiving application by e-mail within 3 working days.
Applicants, who do not receive an e-mail, should make inquiries via the “Inquiries Form”.

Announcement of the results of primary selection

Shionogi will inform all applicants of the results by 17th March 2017 in JST by way of e-mail.

Secondary selection

Application period

20th March 2017 to 21st April 2017 in JST.

Application method

Shionogi will inform applicants, who pass the primary selection round, of the application method.

Announcement of successful applicants

Shionogi will inform all applicants of the results of the secondary selection round by way of e-mail (by 30th June 2017 in JST).

Selection criteria

The selection criteria include: match with the needs of the company; originality of research; feasibility; future potential; the possibility of commercialization and conflicts with existing company projects, etc.

Research period

The research period will be determined after selection, with a maximum of three years as a SHIONOGI Science Program. However, contracts will be renewed each year and the research period may be shortened upon consultation.

Research budgets

Budgets will be a maximum ¥15 million per year per project and will be finalized after selection. Budgets are collaboration research budgets.

The governing law of SHIONOGI Science Program is the laws of England and Wales.

Details of research themes

[Pain 1] An innovative approach to target identification and/or technology platform in drug discovery for pain.

An innovative approach in drug discovery for:

  • a) Target identification
    Targets should have clinical evidence (genetic or pharmacological) for refractory pain.
    Proposals should include target validation in man and translational research from animal to human.
  • b) Technology platform
    The technology platform should be based on clinical features of chronic pain, such as emotional pain and functional pain, definitive therapy or personalized medicine for neuropathic pain, prevention of chronic pain etc. Proposals should include translational research from animal to human.

[Pain 2] An innovative approach to discovery of novel opioid analgesics without central side effects, such as psychological dependence, sedation and respiratory depression.

Proposals are limited to orally available small molecules. Research ideas involving gene therapy approaches or antibody therapy are excluded.

[CNS] A unique bioinformatics method for identifying novel drug targets, biomarkers and the pathogenesis of CNS disorders with an emphasis on research to treat impairment of cognitive functions.

Original bioinformatics methods/protocols using databases containing both brain functions (diagnosis parameters etc.) and molecular information (gene, epigenetic, protein etc.) to identify new drug targets and diagnostic markers related to CNS diseases.
Originality in the data selection approach and/or the power of the analytical method to improve the prediction of outcome is desired.

[Infectious Disease 1] An approach and/or technology to improve gastrointestinal mucosal permeability of beta-lactam antibiotics.

Proposals can be for innovative methods in DDS, absorption enhancement, prodrug approach etc. Proposals must aim for once-a-day administration of target compound(s).

[Infectious Disease 2] A novel approach for a cure (virus eradication) or for a functional cure (permanent suppression of viral replication) of human immunodeficiency virus (HIV) infection.

[Infectious Disease 3] A novel approach for a cure (virus eradication) or for a functional cure (permanent suppression of viral replication) of hepatitis B virus (HBV) infection.

[Infectious Disease 4] A preclinical model of latent HIV infection.

The model must reproduce clinical symptoms in patients.

[Infectious Disease 5] A preclinical model of latent HBV infection.

The model must reproduce clinical symptoms in patients.

[Infectious Disease 6] A preclinical model of chronic human herpesvirus (HHV) infection.

Re-activation of HHV must be controlled in the model.

Application

Please read Shionogi’s privacy policy before submission of your application.

Privacy Policy